In the study of 206 stage IIIb or IV NSCLC patients treated with EGFR-tyrosine kinase inhibitors (gefitinib or erlotinib), stromal TAMs were the predominant CD163+ TAMs (192). Here, EGFR is linked to non-small cell lung carcinoma.